MX354102B - Derivados de bencimidazol-prolina. - Google Patents
Derivados de bencimidazol-prolina.Info
- Publication number
- MX354102B MX354102B MX2014014885A MX2014014885A MX354102B MX 354102 B MX354102 B MX 354102B MX 2014014885 A MX2014014885 A MX 2014014885A MX 2014014885 A MX2014014885 A MX 2014014885A MX 354102 B MX354102 B MX 354102B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- benzimidazole
- proline derivatives
- sub
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente invención hace referencia a compuestos de la fórmula (I) en donde Ar1, R1, R2, R3, R4a, R4b y (R5)n son según se describe en la descripción, a su preparación, a sus sales farmacéuticamente aceptables, y a su uso como productos farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I), y especialmente a su uso como antagonistas de los receptores de la orexina. (ver Fórmula).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12170748 | 2012-06-04 | ||
EP13158520 | 2013-03-11 | ||
PCT/IB2013/054567 WO2013182972A1 (en) | 2012-06-04 | 2013-06-03 | Benzimidazole-proline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014014885A MX2014014885A (es) | 2015-03-05 |
MX354102B true MX354102B (es) | 2018-02-13 |
Family
ID=48914370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014885A MX354102B (es) | 2012-06-04 | 2013-06-03 | Derivados de bencimidazol-prolina. |
Country Status (33)
Country | Link |
---|---|
US (3) | US9732075B2 (es) |
EP (1) | EP2855453B1 (es) |
JP (1) | JP5814491B2 (es) |
KR (3) | KR101946128B1 (es) |
CN (1) | CN104334544B (es) |
AR (1) | AR091257A1 (es) |
AU (1) | AU2013273222B2 (es) |
BR (1) | BR112014030173B1 (es) |
CA (1) | CA2873341C (es) |
CL (1) | CL2014003294A1 (es) |
CY (1) | CY1118735T1 (es) |
DK (1) | DK2855453T3 (es) |
EA (2) | EA029899B1 (es) |
ES (1) | ES2617863T3 (es) |
FR (1) | FR22C1047I2 (es) |
HK (1) | HK1208449A1 (es) |
HR (1) | HRP20170351T1 (es) |
HU (2) | HUE031753T2 (es) |
IL (1) | IL236024A (es) |
LT (2) | LT2855453T (es) |
MX (1) | MX354102B (es) |
MY (1) | MY169986A (es) |
NL (1) | NL301197I2 (es) |
NO (1) | NO2022044I1 (es) |
NZ (1) | NZ703448A (es) |
PH (1) | PH12014502540B1 (es) |
PL (1) | PL2855453T3 (es) |
PT (1) | PT2855453T (es) |
SG (2) | SG11201408004SA (es) |
SI (1) | SI2855453T1 (es) |
TW (2) | TWI510481B (es) |
WO (1) | WO2013182972A1 (es) |
ZA (1) | ZA201409422B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5744203B2 (ja) | 2010-08-24 | 2015-07-08 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 |
TWI510481B (zh) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | 苯并咪唑脯胺酸衍生物 |
KR102151288B1 (ko) | 2012-10-10 | 2020-09-03 | 이도르시아 파마슈티컬스 리미티드 | [오르토 바이 (헤테로 )아릴]-[2-(메타 바이 (헤테로 )아릴)-피롤리딘-1-일]-메타논 유도체인 오렉신 수용체 안타고니스트 |
EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
AU2014295123B2 (en) | 2013-07-22 | 2018-08-02 | Idorsia Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
PT3077389T (pt) | 2013-12-03 | 2017-12-15 | Idorsia Pharmaceuticals Ltd | Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina |
SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
TW201613864A (en) * | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
GEP20186909B (en) * | 2014-02-20 | 2018-10-25 | Pharmaceutical Company Limited Takeda | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
CN107250133B (zh) * | 2015-01-15 | 2020-09-15 | 爱杜西亚药品有限公司 | 作为cxcr3受体调节剂的羟烷基哌嗪衍生物 |
US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
PT4019022T (pt) | 2015-10-01 | 2024-03-11 | Biocryst Pharm Inc | Inibidores da calicreína plasmática humana |
SG11201804223TA (en) | 2015-11-23 | 2018-06-28 | Sunshine Lake Pharma Co Ltd | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
RS62357B1 (sr) | 2017-05-03 | 2021-10-29 | Idorsia Pharmaceuticals Ltd | Dobijanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline |
WO2019002344A1 (en) | 2017-06-29 | 2019-01-03 | Lonza Guangzhou Nansha Ltd. | PROCESS FOR THE PREPARATION OF ALPHA-METHYL-L-PROLINE |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
CN108997308A (zh) * | 2018-07-09 | 2018-12-14 | 西藏大学 | 一种苯并咪唑类衍生物及其制备方法和应用 |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
AU2021260018A1 (en) | 2020-04-19 | 2022-12-22 | Idorsia Pharmaceuticals Ltd | Medical use of daridorexant |
CA3206870A1 (en) * | 2021-02-02 | 2022-08-11 | Wei Wei | Tetrahydropyrrolocyclic compound and application thereof |
WO2023160004A1 (zh) * | 2022-02-25 | 2023-08-31 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
DE60110066T2 (de) | 2000-06-16 | 2006-02-02 | Smithkline Beecham P.L.C., Brentford | Piperidine zur verwendung als orexinrezeptorantagonisten |
US20030055037A1 (en) | 2000-10-06 | 2003-03-20 | Delombaert Stephane | Benzimidazole and indole derivatives as CRF receptor modulators |
DE60108420T2 (de) | 2000-11-28 | 2005-12-22 | Smithkline Beecham P.L.C., Brentford | Morpholinderivate als antagonisten an orexinrezeptoren |
CN100448874C (zh) | 2001-05-05 | 2009-01-07 | 史密斯克莱·比奇曼公司 | N-芳酰基环胺 |
EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
HUP0400326A2 (hu) * | 2001-06-28 | 2004-09-28 | Smithkline Beecham P.L.C. | Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
US20060040937A1 (en) | 2002-09-18 | 2006-02-23 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
AR044586A1 (es) | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
PT1751111E (pt) | 2004-03-01 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina substituída |
WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
KR101065239B1 (ko) | 2006-03-15 | 2011-09-16 | 액테리온 파마슈티칼 리미티드 | 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체 |
WO2008008517A2 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
ES2360376T3 (es) | 2006-08-15 | 2011-06-03 | Actelion Pharmaceuticals Ltd. | Compuestos de azetidina como antagonistas del receptor de orexina. |
WO2008038251A2 (en) * | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
US8124623B2 (en) | 2006-11-10 | 2012-02-28 | Actelion Pharmaceuticals Ltd. | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
JP2010526869A (ja) | 2007-05-14 | 2010-08-05 | アクテリオン ファーマシューティカルズ リミテッド | 2−シクロプロピル−チアゾール誘導体 |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
EP2176258A1 (en) | 2007-07-03 | 2010-04-21 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
KR20100041805A (ko) | 2007-07-03 | 2010-04-22 | 액테리온 파마슈티칼 리미티드 | 3-아자-비시클로[3.3.0]옥탄 화합물 |
US7751938B2 (en) | 2007-07-05 | 2010-07-06 | Panasonic Corporation | Robot arm control device and control method, robot, and control program |
AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
TW200904799A (en) | 2007-07-27 | 2009-02-01 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
JP2010534647A (ja) | 2007-07-27 | 2010-11-11 | アクテリオン ファーマシューティカルズ リミテッド | 2−アザ−ビシクロ[3.3.0]オクタン誘導体 |
EP2207778A2 (en) | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
MX2010006241A (es) | 2007-12-18 | 2010-06-30 | Actelion Pharmaceuticals Ltd | Derivados de aminotriazol como agonistas de alx. |
CA2713184A1 (en) * | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[2.2.1]heptane derivatives |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
US20110212968A1 (en) | 2008-10-14 | 2011-09-01 | Hamed Aissaoui | Phenethylamide derivatives and their heterocyclic analogues |
JP2012506375A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
EP2358713A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
JP2012509911A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
TW201033190A (en) | 2008-12-02 | 2010-09-16 | Glaxo Group Ltd | Novel compounds |
AU2009324238A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
WO2010114978A1 (en) | 2009-04-03 | 2010-10-07 | Merck Sharp & Dohme Corp. | Renin inhibitors |
CA2759160A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists |
KR101444559B1 (ko) | 2009-06-09 | 2014-09-26 | 액테리온 파마슈티칼 리미티드 | 불화 아미노트리아졸 유도체 |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
JP5744203B2 (ja) | 2010-08-24 | 2015-07-08 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 |
WO2012039717A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
KR101873083B1 (ko) | 2011-02-18 | 2018-06-29 | 이도르시아 파마슈티컬스 리미티드 | 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체 |
SI2776430T1 (sl) | 2011-11-08 | 2016-06-30 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja |
TWI510481B (zh) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | 苯并咪唑脯胺酸衍生物 |
KR102151288B1 (ko) | 2012-10-10 | 2020-09-03 | 이도르시아 파마슈티컬스 리미티드 | [오르토 바이 (헤테로 )아릴]-[2-(메타 바이 (헤테로 )아릴)-피롤리딘-1-일]-메타논 유도체인 오렉신 수용체 안타고니스트 |
EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
PT3077389T (pt) * | 2013-12-03 | 2017-12-15 | Idorsia Pharmaceuticals Ltd | Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina |
SI3077391T1 (sl) * | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
-
2013
- 2013-06-03 TW TW102119632A patent/TWI510481B/zh active
- 2013-06-03 NZ NZ703448A patent/NZ703448A/en unknown
- 2013-06-03 PL PL13744805T patent/PL2855453T3/pl unknown
- 2013-06-03 CA CA2873341A patent/CA2873341C/en active Active
- 2013-06-03 AU AU2013273222A patent/AU2013273222B2/en active Active
- 2013-06-03 SI SI201330557A patent/SI2855453T1/sl unknown
- 2013-06-03 SG SG11201408004SA patent/SG11201408004SA/en unknown
- 2013-06-03 PT PT137448056T patent/PT2855453T/pt unknown
- 2013-06-03 DK DK13744805.6T patent/DK2855453T3/en active
- 2013-06-03 JP JP2015515624A patent/JP5814491B2/ja active Active
- 2013-06-03 LT LTEP13744805.6T patent/LT2855453T/lt unknown
- 2013-06-03 EA EA201600366A patent/EA029899B1/ru not_active IP Right Cessation
- 2013-06-03 ES ES13744805T patent/ES2617863T3/es active Active
- 2013-06-03 EP EP13744805.6A patent/EP2855453B1/en active Active
- 2013-06-03 EA EA201401351A patent/EA028046B1/ru not_active IP Right Cessation
- 2013-06-03 CN CN201380029097.2A patent/CN104334544B/zh active Active
- 2013-06-03 US US14/405,649 patent/US9732075B2/en active Active
- 2013-06-03 HU HUE13744805A patent/HUE031753T2/en unknown
- 2013-06-03 SG SG10201702540UA patent/SG10201702540UA/en unknown
- 2013-06-03 MY MYPI2014703599A patent/MY169986A/en unknown
- 2013-06-03 KR KR1020167019098A patent/KR101946128B1/ko active IP Right Grant
- 2013-06-03 BR BR112014030173-5A patent/BR112014030173B1/pt active IP Right Grant
- 2013-06-03 KR KR1020187029604A patent/KR101995683B1/ko active IP Right Grant
- 2013-06-03 MX MX2014014885A patent/MX354102B/es active IP Right Grant
- 2013-06-03 AR ARP130101954 patent/AR091257A1/es active IP Right Grant
- 2013-06-03 WO PCT/IB2013/054567 patent/WO2013182972A1/en active Application Filing
- 2013-06-03 TW TW104132248A patent/TWI570120B/zh active
- 2013-06-03 KR KR1020157000154A patent/KR101689093B1/ko active IP Right Grant
-
2014
- 2014-11-14 PH PH12014502540A patent/PH12014502540B1/en unknown
- 2014-12-02 CL CL2014003294A patent/CL2014003294A1/es unknown
- 2014-12-02 IL IL236024A patent/IL236024A/en active IP Right Grant
- 2014-12-19 ZA ZA2014/09422A patent/ZA201409422B/en unknown
-
2015
- 2015-09-16 HK HK15109034.2A patent/HK1208449A1/xx unknown
-
2017
- 2017-02-28 CY CY20171100269T patent/CY1118735T1/el unknown
- 2017-03-02 HR HRP20170351TT patent/HRP20170351T1/hr unknown
- 2017-07-07 US US15/644,547 patent/US10329287B2/en active Active
-
2019
- 2019-05-07 US US16/405,797 patent/US11040966B2/en active Active
-
2022
- 2022-08-31 LT LTPA2022518C patent/LTPA2022518I1/lt unknown
- 2022-09-01 HU HUS2200040C patent/HUS2200040I1/hu unknown
- 2022-09-13 FR FR22C1047C patent/FR22C1047I2/fr active Active
- 2022-09-28 NL NL301197C patent/NL301197I2/nl unknown
- 2022-10-27 NO NO2022044C patent/NO2022044I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX354102B (es) | Derivados de bencimidazol-prolina. | |
IN2014CN04127A (es) | ||
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
PH12015500627A1 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
IN2014CN04530A (es) | ||
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
MX2021004000A (es) | Derivados de piperidina. | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
WO2013190508A3 (en) | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | |
WO2011138265A3 (en) | Indole and indazole derivatives as orexin receptor antagonists | |
MX2016006509A (es) | Compuestos triciclicos de piperidina. | |
TN2016000061A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
WO2010131192A3 (en) | Novel oxazolidinone derivatives and their use as orexin receptor antagonists | |
UA112586C2 (uk) | Похідні бензімідазолпроліну |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: IDORSIA PHARMACEUTICALS LTD |
|
FG | Grant or registration |